Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by TriSalus Life Sciences TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call August 01, 2024 From TriSalus Life Sciences Via Business Wire Tickers TLSI TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation July 01, 2024 From TriSalus Life Sciences Via Business Wire Tickers TLSI TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants June 26, 2024 From TriSalus Life Sciences Via Business Wire Tickers TLSI TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting June 03, 2024 From TriSalus Life Sciences Via Business Wire Tickers TLSI TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants May 24, 2024 From TriSalus Life Sciences Via Business Wire Tickers TLSI TriSalus Reports Q1 2024 Financial Results and Business Update May 15, 2024 From TriSalus Life Sciences Via Business Wire Tickers TLSI TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors May 07, 2024 From TriSalus Life Sciences Via Business Wire Tickers TLSI TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call May 06, 2024 From TriSalus Life Sciences Via Business Wire Tickers TLSI TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives April 30, 2024 From TriSalus Life Sciences Via Business Wire Tickers TLSI TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update April 01, 2024 From TriSalus Life Sciences Via Business Wire Tickers TLSI TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting March 26, 2024 From TriSalus Life Sciences Via Business Wire Tickers TLSI TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting March 21, 2024 From TriSalus Life Sciences Via Business Wire Tickers TLSI TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101 March 07, 2024 From TriSalus Life Sciences Via Business Wire Tickers TLSI TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors February 29, 2024 From TriSalus Life Sciences Via Business Wire Tickers TLSI TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting October 25, 2023 From TriSalus Life Sciences Via Business Wire Tickers TLSI TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics September 06, 2023 From TriSalus Life Sciences Via Business Wire Tickers TLSI TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation August 10, 2023 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting June 12, 2023 From TriSalus Life Sciences Via Business Wire Tickers MTAC TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases April 20, 2023 From TriSalus Life Sciences Via Business Wire Tickers MTAC TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments December 15, 2022 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies November 21, 2022 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition Corporation November 14, 2022 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Provides Update on Development of Immunotherapy Platform Approach for Liver and Pancreatic Tumors June 22, 2022 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial, Studying the Delivery of SD-101 via Pressure-Enabled Drug Delivery in Adults with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma May 10, 2022 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Expands Clinical Executive Team and Scientific Advisors in Support of Company’s Focus to Overcome Liver and Pancreatic Cancer Treatment Barriers and Enable More Patients to Benefit From Immunotherapy February 10, 2022 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Announces Collaboration with the University of Colorado Anschutz Medical Campus to Advance Research on Innovative Immuno-oncology Treatments for Patients with Liver and Pancreatic Tumors January 20, 2022 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Appoints Industry Expert Sean Murphy to Board of Directors October 05, 2021 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver Metastases September 07, 2021 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Presents Data at American Association of Cancer Research Showing Reduced Liver Tumor Burden from Toll-Like Receptor Agonists April 14, 2021 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences and MD Anderson Announce Strategic Research Collaboration to Evaluate Treatment of Solid Tumors April 08, 2021 From TriSalus Life Sciences Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.